Bridging the group benefits and pharmaceutical industry
Suzanne Lepage Consulting Inc.
  • Home
  • About
  • Private Market
  • Services
  • Resources
  • Contact
Welcome. At Suzanne Lepage Consulting, we're here to help you effectively navigate private health plans.  Whether it be an existing service or a custom solution, we draw on a unique blend of group benefits and pharmaceutical industry experience. 

We understand that the private benefit plan market in Canada is in a state of flux.  Many different market disruptions are changing the dynamic and it can be difficult to monitor the issues and understand the impact it can have on your organization. The private market is complex and there are a variety of influences that impact change. When you understand how the different stakeholders interact you can determine the best way to accomplish your business objectives.


Find out what people are saying about Suzanne.
Picture
Bridging the group benefits and pharmaceutical industry

Suzanne in the news

2019​
  • August 2019:  What will PMPRB drug pricing changes mean for plan sponsors?
  • June 2019: A look at the value of continuous glucose monitoring
  • May 2019: The legal risks of drug plan design changes
  • May 2019: B.C. government says expanding biosimilars will save nearly $100 million over three years
  • February 2019: Top 5 Trends in Health Benefits in 2019
​2018
  • June 2018: Should employers share potential tax burden for pharmacare?
  • April 2018: Have your say: Did Commons committee get it right on pharmacare?
  • ​March 2018: Pharmacare and Private Plans – An Opportunity to Share the Risk?
  •  January 2018: Youth pharmacare plan’s growing pains creating challenges for some patients
2017
  • May 2017: Feds propose regulatory changes to reduce cost of prescription drugs
  • May 2017: Plan members need help with co-ordinating care: report
  • April 2017: Expanded pharmacy services could save health system up to $25B: study
  • April 2017: Loblaw is covering medical marijuana for workers. Will other employers follow?
2016
  • July 2016: Report urges Canada to beef up IP protection for biologics
  • July 2016: A look at the tools to address drug plan cost pressures
2015
  • September 2015: ​Fight for your employees’ health
2014
  • August 2014:  Canadian Leadership Council: Joint Efforts
2013
  • September 2013: Benefits Canada- Canadian Leadership Council on Drug Plan Partnerships:
  • June 2013: Think tank evaluates current methods for drug coverage
  • May 2013: Authentik You Series: Suzanne Lepage, Private Health Plan Strategist
  • February 2013: MHCSI Pharmacy Benefits Roundtable
  • January 2013: Moving toward a healthier drug plan: Enabling survivorship
2012
  • December 2012: Splitting the bill on drug plan costs
  • December 2012: Solutions in Drug Plan Management: It takes two
  • July 2012: Industry leaders weigh in on drug evaluation 
  • March 2012: The reality of chronic disease treatment
  • February 2012: Decision Time 
  • February 2012: MHCSI Pharmacy Benefits Round Table
2011
  • October 2011 Video: Don’t view biologics in isolation
  • 2011: Benefits Canada TV - Biologics – total impact to plans
  • February 2011:   Face to Face - Drug Plan Management Forum
  • February 2011: Rewriting the prescription: creative ways to control drug costs 
  • February 2011: The truth about drug reform 
2010
  • December 2010: Patient’s Voice Event
  • December 2010: Who’s Who in Healthcare Roundtable
  • July 2010: Solutions in Drug Plan Management
2009
  • December 2009: Face to Face - Drug Plan Management Forum 
2008
  • Fall 2008: Bridging the Divide

Suzanne published

2021
  • Green Shield Canada – Pioneer in Biosimilar Policy and Plans - IQVIA Canada Provincial Reimbursement Advisor (PRA) Volume 24, Issue 3 August 2021 (available to subscribers only)
  • Innovative Medicines Canada Cost Drivers Analysis of Private Drug Plans in Canada 2021
  • Health Economics and Private Plans - Balancing Sustainability and Risks – Report from Benefits Canada 2021 Canadian Leadership Council on Drug Plan Partnerships (August 2021)
  • BC - Private and Public Payer Integration and Impact on Pharma Industry-  IQVIA Canada Provincial Reimbursement Advisor (PRA) Volume 24, Issue 2 May 2021 (available to subscribers only)
  • Breaking Down the Facts About Private Drug Plan Costs - IQVIA Canada Provincial Reimbursement Advisor (PRA) Volume 24, Issue 2 May 2021 (available to subscribers only)
  • Private Payer Analysis - IQVIA PharmaFocus 2025 (May 2021) (available to subscribers only)
  • Pharmacy-based diabetes management improves access, outcomes - Benefits Canada Webinar coverage (July 2021)
​
2019
  • August 2019:  Canadian Leadership Council on Drug Plan Partnerships – Partnering for Drug Plan Sustainability
  • August 2019:  Potential Impact of PMPRB Changes from a Regulatory, HTA and Payer Perspective
  • ​March 2019: Competition Bureau looking at protection strategies for biologics market
2018
  • October 2018: Private Drug Plan Drug Cost Forecast (2017-2019), 3rd edition
  • ​August 2018: Cost Drivers Analysis of Private Drug Plans in Canada 2012-2016
  • June 2018: Is nudging biologic patients towards biosimilars a good choice for plan sponsors?
2017
  • January 2017: What to do about biosimilars?
2016
  • May 2016: Dysfunctional Relationships Why Private Drug Plans And Physicians Don't Talk To Each Other
2015
  • June 2015: Breaking through silos in the private health benefit ecosystem 
  • March 2015: Drug Plan Trends in Canada
2014
  • December 2014: Managing the growing risk of opioid addictions
  • January 2014: Patient Assistance Program Primer
2013
  • December 2013: Demystifying private drug plans
  • October 2013: Pharma logic
  • September 2013: Health check
  • June 2013: Helping employees with role overload
  • May 2013: Changing drug plan design: Practical tips to consider 
  • April 2013: Change in health benefits management
  • March 2013: Patient assistance program primer: 
  • February 2013:  Drug plan substations: Handle with care
2012 - 2007
  • 2012: Influenza at Work (Editorial Consultant) 
  • 2011: Therapeutic substitution - will it yield benefits for drug plan sponsors?
  • 2010: Evaluating drugs: Apples vs Oranges 
  • 2010: Changing Oncology Landscape (Article) 
  • February 2010: A Delicate Balance How can plan sponsors weigh the needs of their plan members with the high costs of biologic drugs? 
  • September 2007: Cancer patients need help navigating uncharted waters 

Suzanne's latest tweets

Tweets by @SuzanneLepage
Powered by Create your own unique website with customizable templates.